Chemotherapy plus immunotherapy before and after surgery for stomach or esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining chemotherapy with an immunotherapy drug called durvalumab before and after surgery for stomach or lower esophagus cancer. The goal is to see if this approach helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have stomach, lower esophagus, or junction cancer that can be removed with surgery.
- Your cancer is locally advanced (has grown into nearby tissue or lymph nodes) but has not spread to distant organs.
- You are in good enough health to undergo surgery and treatment (ECOG performance status 0 or 1).
- You have adequate blood counts, liver and kidney function.
- You have not had chemotherapy or immunotherapy for this cancer before.
- You are not pregnant or breastfeeding, and you agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (durvalumab) for esophageal cancer that has spread to a few other places in the body or is too advanced for surgery. It aims to see if this combination helps with swallowing difficulties and slows the cancer's growth.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial tests a new combination of chemotherapy and an immunotherapy drug (durvalumab) given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it shrinks the tumor and improves outcomes.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can improve outcomes for patients with a certain type of stomach or esophageal cancer that can be surgically removed. It aims to see if this approach shrinks tumors and helps prevent recurrence.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
Hear when a new Esophagogastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.